Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Non-Prescription, Breakthrough Cold Sore Medicine to Hit U.S. Shelves This Summer
  • USA - English


News provided by

PR Media

May 26, 2015, 03:00 ET

Share this article

Share toX

Share this article

Share toX


Cherry Hill, NJ (PRWEB) May 26, 2015 -- The brand new, over-the-counter product was developed in Switzerland and will be available in American retail stores for the first time ever this summer. The topical cold sore treatment forms a protective layer over the cold sore, stopping the spread of the virus. Zzip immediately relieves pain and halts itching. http://www.zzipUSA.com

Zzip immediately relieves pain and halts itching

Post this

ZZIP USA is proud to announce that ZZIP® Cold Sore medication will be available to the American consumer for the first time this summer. Zzip’s unique, proprietary and patented blend of natural and synthetic ingredients will extend to the U.S. what Europeans began discovering back in 2014. Zzip was developed and engineered in Switzerland by ZZIP AG amongst the natural beauty of the Swiss Alps. That particular region has a long and noted history for products designed with a keen attention to detail and superior ingredients. The Zzip proprietary and patented formula combines active ingredients Dimethicone, Menthol and Allantoin; along with inactive Alpine Rose extract, among other ingredients.

One cold sore sufferer says: “I have hit the lottery in finding Zzip.” Others say Zzip is unlike anything else they have tried: “Zzip quickly relieved the pain, halted itching and the result was indisputable.” Testimonials include people who have suffered 50 or more years of treating recurring cold sores. They say the product had truly unique attributes in immediate and sustained pain relief. You can hear Tom’s story here.

“In 25 years of creating and marketing a wide variety of supplements, cosmetics and other treatments that address ailments of the human condition,” says OTC Pharma CEO, Mario Oldani, “I have never been associated with a product that I believed has so much organic competitive advantages over the other offerings it competes against.” http://www.zzipUSA.com

Introducing the product in the two countries he calls home, Mario’s assessment proved true as the product quickly shot to the #2 bestselling item in the cold sore treatment/ lip care segment in both Switzerland and the Netherlands. After seeing the success of Zzip in Switzerland and the Netherlands, Boot’s, the U.K.’s largest Drug Store Chain, began carrying Zzip in February. Boot’s is owned by Illinois-based Walgreen’s.

“I remember where I was when I heard the news,” stated Martin Uniacke, VP of Sales of ZZIP USA, the American company that is the Exclusive importer of Zzip. “We were in Las Vegas at a pharmacy sales event focused on the Cough and Cold Category where we were making 80 presentations to many of the biggest mass, chain drug and grocery retailers and their distributors, when were told. A cut-in entry, that is to say an accelerated move to put a product on the shelves in one of the largest retail operations in their home market in Europe was a great show of acceptance and eagerness to want to carry the product.” http://www.zzipUSA.com

Uniacke looks ahead to future events. "We attended the ECRM show for the Cough and Cold Category in February in Hendersonville, NV near Las Vegas. We were well received by Walgreen's, CVS, H.E.B., KMart, Smith Drug and SuperValu, as well as several major distributors and a host of regional independent pharmacies from across the country, many of whom we are following up with now," says Uniacke.

“My decision to invest my time, energy and money into new endeavors are based on whether or not the initiative meets my ‘doing good and doing well’ litmus test. In the case of becoming the exclusive US importer of Zzip, the product surpassed my criteria,” says Garnick, CEO and Founder of GG Advisors, LLC dba ZZIP USA. “Millions of Americans suffer needlessly from cold sore breakouts due to the insidious HSV1 Virus. Most people don't realize that an innocent kiss from Grandmom might have transmitted this incurable virus during ones childhood. Zzip's unique blend of ingredients engineered by a skilled team of doctors and scientists in Switzerland, is an OTC Medicine that we know will help the millions of people who’ve given up on the current available remedies. The products available today simply have proven ineffective for a vast amount of cold sore suffers. We know if cold sore sufferers give Zzip a try that they, like so many Europeans already have experienced who have been using this non-prescription breakthrough medicine since late 2014, will finally get the relief from the painful, embarrassing and untimely cold sores that so many have been struggling with for too long.”

Zzip will be available to American consumers through Amazon in August. In addition, mainstream and local pharmacies across the country will soon carry Zzip, including Hi-School Pharmacy in the Pacific Northwest.

Inquires may contact: Robyn Stevens prmedia(at)live(dot)com 856-885-0913
http://www.zzipUSA.com

Robyn Stevens, PR Media, +1 856.885.0913, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.